New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)

Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news